Featured Research

from universities, journals, and other organizations

UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer

Date:
May 3, 1999
Source:
University Of California, San Francisco
Summary:
Researchers report that four drugs thought to disrupt the formation of blood vessels that fuel tumor growth have been shown for the first time to be effective at treating spontaneous tumors at distinct stages of progression in mice.

Researchers report that four drugs thought to disrupt the formation of blood vessels that fuel tumor growth have been shown for the first time to be effective at treating spontaneous tumors at distinct stages of progression in mice.

The study, reported in the April 30 issue of Science, provides evidence that these drugs, so-called angiogenesis inhibitors, can act against tumors in a mouse model that more closely resembles the conditions of human tumor development than the models previously used.

It also provides the first indication that the drugs vary in their efficacy depending on the stage of cancer targeted - drugs showed encouraging results when used to treat distinct stages of tumor development, including premalignancy. The model could therefore provide a platform for exploring the potential of perhaps even more effective angiogenesis inhibitors, or combinations of inhibitors, not just for the treatment of cancer, but for prevention, the researchers said.

"We've shown that these drugs have beneficial effects when used to treat mice developing organ-specific cancer in which tumors arise from premalignant lesions in their natural tissue microenvironment, representing an important extension of the evidence for efficacy of angiogenesis inhibition in cancer," said the senior author of the study, Douglas Hanahan, Ph.D., a professor of biochemistry at UCSF.

Many angiogenesis inhibitors are currently being investigated in laboratories around the world. If the results continue to be encouraging, said the lead author of the study, Gabriele Bergers, Ph.D., a visiting postdoctoral fellow in the Department of Biochemistry and Biophysics, and the Hormone Research Institute at UC San Francisco, "the strategy will be to determine which anti-angiogenesis compounds are most effective at which stage of cancer in mouse models, and to develop dosing regimens that are fine-tuned to target these specific stages of disease progression."

The ultimate question, of course, the researchers emphasized, is whether the drugs will have similar effects in humans, and the answer is presently unknown. The researchers conducted their study in mice genetically engineered to express a cancer gene, or oncogene, in every insulin-producing islet cell of the pancreas. The result is that they develop a cancer known as islet carcinoma.

The model was created in such a way that new, spontaneous pancreatic tumors continuously emerged, providing a spectrum of disease progression that enabled the researchers to target early-stage cancer cells. (There is a three to four week period before cells expressing an oncogene develop the capability to form solid tumors with invasive, or malignant, properties.)

The premalignant cells in the model were observable, therefore, before they had undergone the "angiogenic switch," the point at which newly forming tumor masses begin emitting signals to recruit blood vessels to fuel their lethal growth. This period may serve as a paradigm for drugs aimed at "preventing" cancer development or recurrence. The classic tumor-transplant models of cancer do not afford this opportunity.

The researchers examined the efficacy of four compounds, AGM-1470, BB-94, angiostatin and endostatin, and a combination of angiostatin and endostatin. The goal of the first stage of the trial was to prevent the angiogenic switch in cells prior to the initial formation of solid tumors; in the second, to intervene in the rapid expansion of small tumors; and in the third to cause regression of large, end-stage cancers. (While each of the drugs acts differently, each in some way inhibits the molecular activity that promotes the growth of new blood vessels.)

In the precancerous lesions, BB-94, endostatin, angiostatin and the combination of angiostatin and endostatin prevented activation of the angiogenic switch in over half of the lesions that otherwise would have turned on the switch.

In the intervention trial, all four drugs were efficacious, impairing tumor growth from 60 percent to 88 percent. (The combination drug was not tested.) In the regression trial, AGM-1470 and the combination of endostatin and angiostatin each produced significant tumor regression in mice with substantial tumors, in contrast to endostatin or angiostatin alone, or BB-94. The former drugs reduced tumor volume by around 60 percent (compared to tumor volume at the starting point of the trial) and by around 72 percent (in untreated mice at end-stage disease).

None of the agents completely prevented the angiogenic switch in the precancerous stage, or blocked the growth of small tumors, or completely resolved lethal tumor burden. The fact that the treated mice still had cancer is not surprising, the researchers said, for two reasons: First, the time course of the trials was limited by design and by limited availability of the experimental drugs. Second, there was a relentless emergence and progression of new spontaneous pancreatic tumors due to the characteristics of the model, wherein tumor development is set in motion by an oncogene in virtually all of the 500,000 pancreatic islet cells.

"Our findings are encouraging about the potential value of angiogenesis inhibitors for treating cancer; we believe we can do even better," said Hanahan. "We've illustrated an approach to cancer therapy and prevention with this model that should be applicable to other mouse models of cancer, and in turn will hopefully guide the development of better ways to treat human cancers."

The study was conducted as part of the ongoing collaboration of the Hanahan laboratory at UCSF and that of Judah Folkman, M.D., at Children's Hospital Medical Center and Harvard Medical School. Folkman has pioneered the field of angiogenesis research and its application to cancer.

Other co-authors of the study were Kashi Javaherian, Ph.D., research associate in the Department of Surgery, Children's Hospital Medical Center and Harvard Medical School, Kin-Ming Lo, Ph.D., vice president of research of Lexigen Pharmaceuticals Corp.

The study was funded by grants from the National Cancer Institute.


Story Source:

The above story is based on materials provided by University Of California, San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University Of California, San Francisco. "UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer." ScienceDaily. ScienceDaily, 3 May 1999. <www.sciencedaily.com/releases/1999/05/990503041854.htm>.
University Of California, San Francisco. (1999, May 3). UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/05/990503041854.htm
University Of California, San Francisco. "UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer." ScienceDaily. www.sciencedaily.com/releases/1999/05/990503041854.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins